A recently completed clinical trial, published in the New England Journal of Medicine indicates that treatment with an immunotherapy drug "may nearly double the length of time people with high-risk muscle-invasive bladder cancer are cancer-free following surgical removal of the bladder." According to Dr. Andrea Apolo from the National Cancer Institute, the drug in question, pembrolizumab, extension of the cancer-free period makes a considerable difference in the patient's quality of life.
To read more about this trial, click here.
Source mentioned:
No comments:
Post a Comment